1. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. Circulation. 2009; 119:2936–44.

2. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010; 10:1420–7.

3. Van Wagner LB, Lapin B, Levitsky J, Wilkins JT, Abecassis MM, Skaro AI, et al. High early cardiovascular mortality after liver transplantation. Liver Transpl. 2014; 20:1306–16.

4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34:274–85.

5. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10:330–44.

6. Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014; 11:177–86.

7. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 1996; 24:451–9.

8. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart. 2002; 87:9–15.
9. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008; 57:268–78.

10. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol. 2001; 36:785–94.

11. Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol. 2012; 6:57–66.

12. Zaky A, Bendjelid K. Appraising cardiac dysfunction in liver transplantation: an ongoing challenge. Liver Int. 2015; 35:12–29.

13. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond). 1999; 97:259–67.

14. Ripoll C, Yotti R, Bermejo J, Bañares R. The heart in liver transplantation. J Hepatol. 2011; 54:810–22.

15. Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant. 2008; 8:1523–8.

16. Safadi A, Homsi M, Maskoun W, Lane KA, Singh I, Sawada SG, et al. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery. Circulation. 2009; 120:1189–94.

17. Nicolau-Raducu R, Gitman M, Ganier D, Loss GE, Cohen AJ, Patel H, et al. Adverse cardiac events after orthotopic liver transplantation: a cross-sectional study in 389 consecutive patients. Liver Transpl. 2015; 21:13–21.

18. Aydinalp A, Bal U, Atar I, Ertan C, Aktaş A, Yildirir A, et al. Value of stress myocardial perfusion scanning in diagnosis of severe coronary artery disease in liver transplantation candidates. Transplant Proc. 2009; 41:3757–60.

19. Davidson CJ, Gheorghiade M, Flaherty JD, Elliot MD, Reddy SP, Wang NC, et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol. 2002; 89:359–60.

20. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet. 1993; 341:1423–8.
21. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998; 27:28–34.

22. Zierler K, Wu FS. Insulin acts on Na, K, and Ca currents. Trans Assoc Am Physicians. 1988; 101:320–5.
23. Zhong J, Hwang TC, Adams HR, Rubin LJ. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol. 1997; 273:H2312–24.
24. Shin WJ, Kim YK, Song JG, Kim SH, Choi SS, Song JH, et al. Alterations in QT interval in patients undergoing living donor liver transplantation. Transplant Proc. 2011; 43:170–3.

25. Lee HM, Park SK, Moon YJ, Kim JW, Kim SK, Sang BH, et al. Arrhythmogenic potential develops rapidly at graft reperfusion before the start of hypotension during living-donor liver transplantation. Korean J Anesthesiol. 2016; 69:37–43.

26. Berger RD, Kasper EK, Baughman KL, Marban E, Calkins H, Tomaselli GF. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation. 1997; 96:1557–65.
27. Huh IY, Park ES, Kim KI, Lee AR, Hwang GS. Alteration of the QT variability index in end-stage liver disease. Korean J Anesthesiol. 2014; 66:199–203.

28. Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C, et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013; 58:51–7.

29. Shin WJ, Song JG, Jun IG, Moon YJ, Kwon HM, Jung K, et al. Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: analysis of pressure-volume curve relations. J Hepatol. 2017; 66:328–37.

30. Bushyhead D, Kirkpatrick JN, Goldberg D. Pretransplant echocardiographic parameters as markers of posttransplant outcomes in liver transplant recipients. Liver Transpl. 2016; 22:316–23.

31. Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int. 2013; 33:1158–65.

32. Jansen C, Cox A, Schueler R, Schneider M, Lehmann J, Praktiknjo M, et al. Increased myocardial contractility identifies decompensated cirrhotic patients requiring liver transplantation. Liver Transpl. 2018; 24:15–25.
33. Dowsley TF, Bayne DB, Langnas AN, Dumitru I, Windle JR, Porter TR, et al. Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation. Transplantation. 2012; 94:646–51.

34. Starling MR. Left ventricular-arterial coupling relations in the normal human heart. Am Heart J. 1993; 125:1659–66.

35. Sagawa K, Suga H, Shoukas AA, Bakalar KM. End-systolic pressure/volume ratio: a new index of ventricular contractility. Am J Cardiol. 1977; 40:748–53.

36. Chen CH, Fetics B, Nevo E, Rochitte CE, Chiou KR, Ding PA, et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. 2001; 38:2028–34.

37. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992; 86:513–21.

38. Yotti R, Ripoll C, Benito Y, Catalina MV, Elízaga J, Rincón D, et al. Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. Hepatology. 2017; 65:2019–30.

39. Jensen MT, Suadicani P, Hein HO, Gyntelberg F. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart. 2013; 99:882–7.

40. Greenland P, Daviglus ML, Dyer AR, Liu K, Huang CF, Goldberger JJ, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. Am J Epidemiol. 1999; 149:853–62.

41. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372:817–21.

42. Jensen MT, Marott JL, Allin KH, Nordestgaard BG, Jensen GB. Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: the Copenhagen City Heart Study. Eur J Prev Cardiol. 2012; 19:102–8.

43. Mani AR, Montagnese S, Jackson CD, Jenkins CW, Head IM, Stephens RC, et al. Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2009; 296:G330–8.

44. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010; 53:179–90.

45. Kim YK, Lee K, Hwang GS, Cohen RJ. Sympathetic withdrawal is associated with hypotension after hepatic reperfusion. Clin Auton Res. 2013; 23:123–31.

46. Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol. 2007; 292:H2966–72.

47. Song JG, Kim YK, Shin WJ, Hwang GS. Changes in cardiovagal baroreflex sensitivity are related to increased ventricular mass in patients with liver cirrhosis. Circ J. 2012; 76:2807–13.

48. Trevisani F, Sica G, Mainquà P, Santese G, De Notariis S, Caraceni P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology. 1999; 30:1387–92.

49. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology. 1994; 20:1359–63.

50. Kwon HM, Jun IG, Jung KW, Moon YJ, Shin WJ, Song JG, et al. Pretransplant resting heart rate and its association with all-causemortality in liver transplant recipients. Transplant Proc. 2017; 49:1092–6.
51. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg. 1996; 2:426–30.

52. An J, Shim JH, Kim SO, Lee D, Kim KM, Lim YS, et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. Circulation. 2014; 130:1353–62.
53. Kazankov K, Munk K, Øvrehus KA, Jensen JM, Siggaard CB, Grønbaek H, et al. High burden of coronary atherosclerosis in patients with cirrhosis. Eur J Clin Invest. 2017; 47:565–73.

54. Kong YG, Kang JW, Kim YK, Seo H, Lim TH, Hwang S, et al. Preoperative coronary calcium score is predictive of early postoperative cardiovascular complications in liver transplant recipients. Br J Anaesth. 2015; 114:437–43.

55. Kong YG, Ha TY, Kang JW, Hwang S, Lee SG, Kim YK. Incidence and predictors of increased coronary calcium scores in liver transplant recipients. Transplant Proc. 2015; 47:1933–8.